GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Grace Therapeutics, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.88−0.01 (-0.53%)
Close on Oct 19, 2026
- Market cap
- $32.47M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.24 (−39.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $32.47M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.67
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$20.22M
- EPS, diluted
- -$1.18
- Book value per share
- $2.79
- Diluted shares
- 17M
Ten years at a glance
Fiscal years 2016 to 2026 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$23.91M
Net income
-$20.22M
EPS, diluted
-$1.18
Reported periodTrailing twelve months